These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 21328449)
1. Nuclear protein isoforms: implications for cancer diagnosis and therapy. Shen F; Kirmani KZ; Xiao Z; Thirlby BH; Hickey RJ; Malkas LH J Cell Biochem; 2011 Mar; 112(3):756-60. PubMed ID: 21328449 [TBL] [Abstract][Full Text] [Related]
2. C-myc and tumour suppressor gene product expression in developing and term human trophoblast. Roncalli M; Bulfamante G; Viale G; Springall DR; Alfano R; Comi A; Maggioni M; Polak JM; Coggi G Placenta; 1994 Jun; 15(4):399-409. PubMed ID: 7937596 [TBL] [Abstract][Full Text] [Related]
3. CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Abbas T; Shibata E; Park J; Jha S; Karnani N; Dutta A Mol Cell; 2010 Oct; 40(1):9-21. PubMed ID: 20932471 [TBL] [Abstract][Full Text] [Related]
4. [A study of expression of p53, c-myc and PCNA in retinoblastoma]. Yang X; Zhang Z; Zeng Q Zhonghua Yan Ke Za Zhi; 1999 Jul; 35(4):252-4, 14. PubMed ID: 11835814 [TBL] [Abstract][Full Text] [Related]
5. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. Stiewe T; Stanelle J; Theseling CC; Pollmeier B; Beitzinger M; PĆ¼tzer BM J Biol Chem; 2003 Apr; 278(16):14230-6. PubMed ID: 12584188 [TBL] [Abstract][Full Text] [Related]
6. Differential regulation of p53-dependent and -independent proliferating cell nuclear antigen gene transcription by 12 S E1A oncoprotein requires CBP. Karuppayil SM; Moran E; Das GM J Biol Chem; 1998 Jul; 273(28):17303-6. PubMed ID: 9651310 [TBL] [Abstract][Full Text] [Related]
7. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma]. Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346 [TBL] [Abstract][Full Text] [Related]
8. Targeting post-translational modifications of histones for cancer therapy. Hsu YC; Hsieh YH; Liao CC; Chong LW; Lee CY; Yu YL; Chou RH Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):69-84. PubMed ID: 26518898 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma. Ioachim E; Charchanti A; Stavropoulos NE; Skopelitou A; Athanassiou ED; Agnantis NJ Histol Histopathol; 2000 Jul; 15(3):721-7. PubMed ID: 10963116 [TBL] [Abstract][Full Text] [Related]
10. Regulating tumor suppressor genes: post-translational modifications. Chen L; Liu S; Tao Y Signal Transduct Target Ther; 2020 Jun; 5(1):90. PubMed ID: 32532965 [TBL] [Abstract][Full Text] [Related]
11. Post-translational modifications on the retinoblastoma protein. Zhou L; Ng DS; Yam JC; Chen LJ; Tham CC; Pang CP; Chu WK J Biomed Sci; 2022 Jun; 29(1):33. PubMed ID: 35650644 [TBL] [Abstract][Full Text] [Related]
12. Potentially malignant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p53, and c-myc in differentiation and prognosis. de Rosa I; Staibano S; Lo Muzio L; Delfino M; Lucariello A; Coppola A; De Rosa G; Scully C J Oral Pathol Med; 1999 Jul; 28(6):252-8. PubMed ID: 10426197 [TBL] [Abstract][Full Text] [Related]
13. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521 [TBL] [Abstract][Full Text] [Related]
14. Regulation of DNA damage tolerance in mammalian cells by post-translational modifications of PCNA. Kanao R; Masutani C Mutat Res; 2017 Oct; 803-805():82-88. PubMed ID: 28666590 [TBL] [Abstract][Full Text] [Related]
15. Cross-talk between T-Ag presence and pRb family and p53/p73 signaling in mouse and human medulloblastoma. Caracciolo V; Macaluso M; D'Agostino L; Montanari M; Scheff J; Reiss K; Khalili K; Giordano A J Cell Biochem; 2010 May; 110(1):182-90. PubMed ID: 20336668 [TBL] [Abstract][Full Text] [Related]
16. p53 modifications: exquisite decorations of the powerful guardian. Liu Y; Tavana O; Gu W J Mol Cell Biol; 2019 Jul; 11(7):564-577. PubMed ID: 31282934 [TBL] [Abstract][Full Text] [Related]
17. The nature of the cardiac myxoma. Suvarna SK; Royds JA Int J Cardiol; 1996 Dec; 57(3):211-6. PubMed ID: 9024908 [TBL] [Abstract][Full Text] [Related]
18. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Jayasurya R; Francis G; Kannan S; Lekshminarayanan K; Nalinakumari KR; Abraham T; Abraham EK; Nair MK Int J Cancer; 2004 May; 109(5):710-6. PubMed ID: 14999779 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699 [TBL] [Abstract][Full Text] [Related]
20. Nuclear protein phosphorylation and growth control. Meek DW; Street AJ Biochem J; 1992 Oct; 287 ( Pt 1)(Pt 1):1-15. PubMed ID: 1417761 [No Abstract] [Full Text] [Related] [Next] [New Search]